NCT04193930

Brief Summary

During assisted reproduction technology treatments like in vitro fertilization, some patients give a poor ovarian response to controlled ovarian hyperstimulation. The European Society of Human Reproduction and Embryology consensus defined poor response to ovarian stimulation during in vitro fertilization with Bologna criteria. Bologna criteria: At least two of the following three features must be present: (i) Advanced maternal age (≥40 years). (ii) Previous Poor responders (≤3 oocytes with a conventional stimulation protocol). (iii) An abnormal ovarian reserve test Most controlled ovarian hyperstimulation regimens currently used for expected poor responders are based on using a high daily dose (300- 450 IU/day) of exogenous gonadotropins. Giving a high gonadotropin dose obviously increases the cost of in vitro fertilization, a consequence that would be acceptable if paralleled by an improvement in in vitro fertilization outcome. Unfortunately, however, the available data suggest that increasing the daily gonadotropins dose may increase the number of retrieved oocytes, but not the final success rate of in vitro fertilization.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 7, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 10, 2019

Completed
1.1 years until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2021

Completed
Last Updated

November 30, 2022

Status Verified

November 1, 2022

Enrollment Period

Same day

First QC Date

December 7, 2019

Last Update Submit

November 26, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total gonadotrophins dose

    14 days

Secondary Outcomes (2)

  • Duration of ovarian stimulation

    14 days

  • Endometrial thickness

    14 days

Study Arms (2)

Soft ovarian stimulation protocol

OTHER
Drug: LetrozoleDrug: Menotropins

conventional ovarian stimulation protocol

OTHER
Drug: MenotropinsDrug: recombinant Follicular stimulating hormone

Interventions

Oral tablet letrozole 2,5 mg/twice daily for 5 days

Soft ovarian stimulation protocol

150 IU of highly purified menotropins intramuscular

Soft ovarian stimulation protocolconventional ovarian stimulation protocol

recombinant Follicular stimulating hormone 300- 400 IU

conventional ovarian stimulation protocol

Eligibility Criteria

Age40 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Advanced maternal age (≥40 years) .
  • Previous Poor responders (≤3 oocytes with a conventional stimulation protocol).
  • An abnormal ovarian reserve tests

You may not qualify if:

  • Hyper or Normal responders patients.
  • Endocrine or metabolic diseases like hyperprolactinoma, hypothyroidism,...etc
  • Patients with a severe male factor abnormality. 4-Patients with systemic disease such as chronic renal disease, chronic liver disease, etc

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Women Health Hospital - Assiut university

Asyut, 71111, Egypt

Location

MeSH Terms

Interventions

LetrozoleMenotropins

Intervention Hierarchy (Ancestors)

NitrilesOrganic ChemicalsTriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsGonadotropins, PituitaryGonadotropinsPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPituitary Hormones, AnteriorPituitary HormonesPeptidesAmino Acids, Peptides, and ProteinsBiological ProductsComplex Mixtures
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

December 7, 2019

First Posted

December 10, 2019

Study Start

January 1, 2021

Primary Completion

January 1, 2021

Study Completion

January 1, 2021

Last Updated

November 30, 2022

Record last verified: 2022-11

Locations